Iben Spanggaard

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 18

Top Topics

Urinary Tract Infection

Positive Breast Cancer

Tyrosine Kinase

Top Venues

Nature medicine

Nature communications

Science translational medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Jordi Rodon Ahnert, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nature medicine 30 (6) (2024)
Jordi Rodon Ahnert, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nature medicine 30 (6) (2024)
Jordi Rodon Ahnert, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal
Publisher Correction: Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nature medicine (2024)
Jordi Rodon Ahnert, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nature medicine (2024)
Jordi Rodon Ahnert, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nature medicine 30 (6) (2024)
Jordi Rodon Ahnert, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nature medicine 30 (6) (2024)
Jordi Rodon Ahnert, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nature medicine (2024)
Jordi Rodon Ahnert, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nature medicine (2024)
Jordi Rodon Ahnert, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nature medicine 30 (6) (2024)
Jordi Rodon Ahnert, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal
Publisher Correction: Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nature medicine (2024)
Jordi Rodon Ahnert, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal
Publisher Correction: Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nature medicine (2024)
Jordi Rodon Ahnert, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal
Publisher Correction: Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nature medicine (2024)
James J Harding, Sarina A Piha-Paul, Ronak H Shah, Jessica J Murphy, James M Cleary, Geoffrey I Shapiro, David I Quinn, Irene Braña, Victor Moreno, Mitesh Borad, Sherene Loi, Iben Spanggaard, Haeseong Park, James M Ford, Mónica Arnedos, Salomon M Stemmer, Christelle De La Fouchardière, Christos Fountzilas, Jie Zhang, Daniel DiPrimeo, Casey Savin, S Duygu Selcuklu, Michael F Berger, Lisa D Eli, Funda Meric-Bernstam, Komal Jhaveri, David B Solit, Ghassan K Abou-Alfa
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers. Nature communications 14 (1) (2023)
James J Harding, Sarina A Piha-Paul, Ronak H Shah, Jessica J Murphy, James M Cleary, Geoffrey I Shapiro, David I Quinn, Irene Braña, Victor Moreno, Mitesh Borad, Sherene Loi, Iben Spanggaard, Haeseong Park, James M Ford, Mónica Arnedos, Salomon M Stemmer, Christelle De La Fouchardière, Christos Fountzilas, Jie Zhang, Daniel DiPrimeo, Casey Savin, S Duygu Selcuklu, Michael F Berger, Lisa D Eli, Funda Meric-Bernstam, Komal Jhaveri, David B Solit, Ghassan K Abou-Alfa
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers. Nature communications 14 (1) (2023)
Ignacio Melero Bermejo, Tamara Tanos, Mariana Bustamante, Miguel F Sanmamed, Emiliano Calvo, Irene Moreno-Candilejo, Victor Moreno, Tatiana Hernández, Maria Martinez-García, Alejo Rodriguez-Vida, Josep Tabernero, Analia Azaro, Mariano Ponz-Sarvisé, Iben Spanggaard, Kristoffer Staal Rohrberg, Ernesto Guarin, Eveline Nüesch, Iakov I Davydov, Chia-Huey Ooi, José Duarte, Evelyne Chesne, Christine McIntyre, Maurizio Ceppi, Marta Cañamero, Oliver Krieter
A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors. Science translational medicine 15 (695) (2023)
James J Harding, Sarina A Piha-Paul, Ronak H Shah, Jessica J Murphy, James M Cleary, Geoffrey I Shapiro, David I Quinn, Irene Braña, Victor Moreno, Mitesh Borad, Sherene Loi, Iben Spanggaard, Haeseong Park, James M Ford, Mónica Arnedos, Salomon M Stemmer, Christelle De La Fouchardière, Christos Fountzilas, Jie Zhang, Daniel DiPrimeo, Casey Savin, S Duygu Selcuklu, Michael F Berger, Lisa D Eli, Funda Meric-Bernstam, Komal Jhaveri, David B Solit, Ghassan K Abou-Alfa
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers. Nature communications 14 (1) (2023)
James J Harding, Sarina A Piha-Paul, Ronak H Shah, Jessica J Murphy, James M Cleary, Geoffrey I Shapiro, David I Quinn, Irene Braña, Victor Moreno, Mitesh Borad, Sherene Loi, Iben Spanggaard, Haeseong Park, James M Ford, Mónica Arnedos, Salomon M Stemmer, Christelle De La Fouchardière, Christos Fountzilas, Jie Zhang, Daniel DiPrimeo, Casey Savin, S Duygu Selcuklu, Michael F Berger, Lisa D Eli, Funda Meric-Bernstam, Komal Jhaveri, David B Solit, Ghassan K Abou-Alfa
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers. Nature communications 14 (1) (2023)
Ignacio Melero Bermejo, Tamara Tanos, Mariana Bustamante, Miguel F Sanmamed, Emiliano Calvo, Irene Moreno-Candilejo, Victor Moreno, Tatiana Hernández, Maria Martinez-García, Alejo Rodriguez-Vida, Josep Tabernero, Analia Azaro, Mariano Ponz-Sarvisé, Iben Spanggaard, Kristoffer Staal Rohrberg, Ernesto Guarin, Eveline Nüesch, Iakov I Davydov, Chia-Huey Ooi, José Duarte, Evelyne Chesne, Christine McIntyre, Maurizio Ceppi, Marta Cañamero, Oliver Krieter
A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors. Science translational medicine 15 (695) (2023)